Gilead Sciences has entered into a strategic licensing agreement with Kymera Therapeutics to accelerate the development of a novel molecular glue degrader (MGD) programme targeting cyclin-dependent kinase 2 (CDK2), a protein implicated in tumour growth, for the treatment of breast cancer and other solid tumours. Under the terms of the deal, Kymera is eligible to receive up to US$750 M, including US$85 M in upfront, potential option exercise payments, and tiered royalties on net sales. This deal enables Gilead to enhance its footprint in the oncology space and accelerate global development.